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normalized ratio, elderly >65 years, drugs/alco‑
hol concomitantly), or a single strong risk factor 
for bleeding. In patients after VTE, other bleeding 
risk factors, in particular menorrhagia in wom‑
en, were present.
A total of 36 patients agreed to switch to apix‑
aban therapy. Patients with a history of recurrent 
bleedings were switched to apixaban at a dose 
of 2.5 mg twice daily, while patients with high 
thromboembolic risk, especially those after isch‑
emic stroke, were switched to apixaban at a dose 
of 5 mg twice daily. The patients switched to apix‑
aban were matched for age, sex, bleeding risk, and 
indications for anticoagulation, with 36 partici‑
pants recruited at the same time who served as 
a control group. These patients refused to start 
treatment with apixaban largely due to no reim‑
bursement for this anticoagulant in Poland, and 
they preferred to continue VKAs or use other less 
expensive non–vitamin K antagonists oral anti‑
coagulants (NOACs) at reduced doses (ie, dabig‑
atran, 110 mg twice daily, or rivaroxaban, 15 mg 
once daily).
During follow ‑up, we recorded major bleeding 
and clinically relevant non–major (CRNM) bleed‑
ing defined according to the International Society 
on Thrombosis and Haemostasis criteria.4 Men‑
orrhagia was defined as self ‑reported bleeding 
which occurred at normal intervals but lasted 
more than 7 days.5 New documented stroke and 
VTE episode were also recorded. The follow ‑up 
was censored at the time of bleeding or throm‑
boembolic episode.
Statistical analysis Continuous variables were 
expressed as mean (SD) or median and inter‑
quartile range (IQR). Normality was assessed 
by the Shapiro–Wilk test. Differences between 
the groups were compared using the t test for 
normally distributed variables. The Mann–Whit‑
ney test was used for nonnormally distributed 
continuous variables. Categorical variables were 
Introduction Recent registries and observational 
studies increasingly support the view that apixa‑
ban has the most favorable safety profile among 
all age groups.1,2 The AVERROES trial3 showed 
that in patients with atrial fibrillation (AF) who 
were unsuitable for treatment with vitamin K an‑
tagonists (VKAs), apixaban compared with aspi‑
rin was associated with a lower risk of stroke and 
similar risk of major bleeding.3 We aimed to as‑
sess the efficacy and safety of the treatment with 
apixaban in real ‑life Polish patients at high bleed‑
ing risk compared with those who received other 
therapeutic options.
Material and methods Patients We enrolled 
patients with AF or venous thromboembolism 
(VTE) at high bleeding risk and unstable anti‑
coagulation while on warfarin or acenocouma‑
rol, who were referred to the Center for Coagu‑
lation Disorders at the John Paul II Hospital in 
Kraków, Poland, between June 2014 and Novem‑
ber 2016. The inclusion criteria were indications 
for long ‑term anticoagulation, namely, for AF: 
≥2 points for male sex and ≥3 points for female 
sex in the CHA2DS2 ‑VASc score (congestive heart 
failure, hypertension, age ≥75 [doubled], diabe‑
tes, stroke, vascular disease, age 65–74, and sex 
[female]); or for VTE: recurrent unprovoked dis‑
ease or severe thrombophilia ‑associated prox‑
imal deep vein thrombosis and/or pulmonary 
embolism, combined with the time in therapeu‑
tic range of less than 50%. The exclusion criteria 
were acute coronary syndrome or stroke within 
the preceding 6 months, active malignancy, cur‑
rent alcohol abuse, and chronic kidney disease 
stage 4 or 5. The local bioethics committee ap‑
proved the study. All patients signed written in‑
formed consent.
A high bleeding risk was defined as 3 points 
or higher in the HAS ‑BLED score (hypertension, 
abnormal renal/liver function, stroke, bleeding 
history or predisposition, labile international 
RESEARCH LETTER
Efficacy and safety of apixaban in real ‑life 
patients at high bleeding risk
Agata H. Bryk1,2*, Robert Łukaszuk1*, Paulina Donicz2, Krzysztof Plens3, Anetta Undas1,2
1  John Paul II Hospital, Kraków, Poland
2  Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland
3  Data Analysis Center, Krakow Cardiovascular Research Institute, Kraków, Poland
Correspondence to:
Agata H. Bryk, MD,  
Instytut Kardiologii, Uniwersytet 
Jagielloński, Collegium Medicum, 
ul. Prądnicka 80, 31-202 Kraków, 
Poland, phone: +48 12 614 30 04, 
email: agata.bryk@uj.edu.pl
Received: October 24, 2017.
Revision accepted:  
November 20, 2017.
Published online: 
December 15, 2017.
Conflict of interests: AU received 
speaker honoraria from Bayer, 
Boehringer Ingelheim, Bristol Myers 
Squibb, Pfizer, and Sanofi ‑Aventis.
Pol Arch Intern Med. 2017; 
127 (12): 889-891
doi:10.20452/pamw.4169
Copyright by Medycyna Praktyczna, 
Kraków 2017
* AB and RŁ contributed equally to 
this work.
POLISH ARCHIVES OF INTERNAL MEDICINE 2017; 127 (12)890
controls (1.9%/year and 15.1%/year, respectively; 
HR, 0.14; 95% CI, 0.01–0.76; P = 0.02). One con‑
trol patient treated with rivaroxaban who experi‑
enced a gastrointestinal bleeding died during hos‑
pitalization. Other types of bleeding were com‑
parable among the study groups.
There were 8 thromboembolic events (22.2%) 
during the follow ‑up, that is, 4 in each group. In 
the apixaban group, we observed 2 transient isch‑
emic attacks (TIAs), 1 minor stroke, and 1 recur‑
rent deep vein thrombosis episode, all on apixa‑
ban at a dose of 2.5 mg twice daily. In the control 
group, there were 2 strokes and 1 TIA, 2 at an in‑
ternational normalized ratio of less than 2 during 
VKA therapy and 1 TIA on rivaroxaban (Supple‑
mentary material, Table S2). The rate of thrombo‑
embolic events was similar in both groups (7.7%/
year and 7.6%/year, respectively; HR, 1.30; 95% 
CI, 0.30–5.71; P = 0.7). The risk of thromboembol‑
ic episodes was similar among patients on apixa‑
ban and those on dabigatran at a dose of 110 mg 
twice daily and rivaroxaban at a dose of 15 mg daily.
Discussion Our study demonstrated that in real‑
‑life patients at high bleeding risk, the risk of ma‑
jor or CRNM bleeding on apixaban was reduced by 
77% compared with the other anticoagulant reg‑
imens, including VKA, dabigatran (110 mg twice 
daily), and rivaroxaban (15 mg daily). In a previ‑
ous study, the risk of major bleeding on apixaban, 
compared with other NOACs, was reduced simi‑
larly in patients with a HAS ‑BLED score of 3 or 
higher and those with a HAS ‑BLED score of 0 to 
2 points.6 In contrast to this large ‑scale study us‑
ing administrative claims, we conducted a prospec‑
tive real ‑life study with complete clinical charac‑
teristics of the participants and took into consid‑
eration also the rate of non–major bleedings, asso‑
ciated with an increased risk of death.7 In patients 
on NOACs mostly with a HAS ‑BLED score below 
3, Abraham et al8 showed that apixaban was as‑
sociated with a 61% lower risk of gastrointestinal 
bleeding than dabigatran. We extended those ob‑
servations onto patients with 3 or more points in 
the HAS ‑BLED score. Previous findings suggest‑
ed a superior benefit ‑to ‑risk profile with the lower‑
‑dose apixaban regimen than with the high ‑dose 
regimen.9 The safety profile achieved by reduc‑
ing the dose of apixaban was not associated with 
a higher risk of thromboembolic events compared 
with controls on VKAs, dabigatran (110 mg twice 
daily) and rivaroxaban (15 mg daily). However, all 
thromboembolic episodes during the follow ‑up in 
our study occurred in patients with a high risk of 
stroke treated with apixaban (2.5 mg twice daily). It 
indicated that reduced doses of apixaban may con‑
vey a relatively high thromboembolic risk which 
is typically associated with a high bleeding risk.
The study has several limitations, including 
wide CIs of the calculated HRs, indicating low 
precision of our estimations due to a small sam‑
ple size, arbitrary use of normal or reduced apixa‑
ban doses, and the possibility of omitting asymp‑
tomatic thromboembolic events.
presented as numbers and percentages and com‑
pared by the Fisher exact test for 2×2 tables or 
by the Pearson χ2 test for other tables. The rate 
of bleeding (%/year) was calculated using the fol‑
lowing formula: the number of bleeding episodes 
in the group divided by the product of number 
of patients in the group and number of years of 
follow ‑up multiplied by 100. Bivariate Cox pro‑
portional hazards regression models were used 
to calculate the hazard ratios (HRs) of predic‑
tive factors and their 95% confidence intervals 
(CIs) for the incidence of clinical events. A 2 ‑sided 
P value was considered statistically significant. 
All calculations were done with JMP®, Version 
12.2.0 (SAS Institute Inc., Cary, North Carolina, 
United States, 1989–2007).
Results Baseline The characteristics of the study 
groups are presented in TABLE 1. The  medi‑
an HAS ‑BLED score was 4 (IQR, 3–5), and 
a HAS ‑BLED score of 3 or more was observed in 
the majority of patients with AF (TABLE 1). The high 
bleeding risk in the other 3 patients with AF result‑
ed from previous intracranial bleeding, von Wille‑
brand disease in the second patient, and alcohol‑
‑related liver disease in the third patient. Among 
patients switched to apixaban at a dose of 2.5 mg 
twice daily (n = 26, 72.2%), there were fewer pa‑
tients with previous stroke (4 [15.4%] vs 6 [60%], 
P = 0.01) compared with those on the 5 ‑mg dose 
(10 [27.8%]). Patients on apixaban at a dose of 
2.5 mg twice daily did not fulfill the criteria for re‑
duced doses according to the product characteris‑
tics. In the control group, there were 7 patients 
(19.4%) on VKAs, 18 patients (50%) on dabiga‑
tran at a dose of 110 mg twice daily, and 11 pa‑
tients (30.5%) receiving rivaroxaban at a dose of 
15 mg daily.
Follow ‑up The median follow‑up was 17 months 
(IQR, 14–21 months). A total of 18 patients (25%) 
reported major or CRNM bleeding, including 9 
gastrointestinal (12.5%) bleedings, 4 heavy men‑
strual bleedings (5.6%), 1 intracranial hemor‑
rhage (1.4%), 1 hemoptysis (1.4%), and 3 other 
bleedings (4.2%) (Supplementary material, Table 
S1). There were fewer CRNM or major bleedings 
among patients on apixaban compared with con‑
trols (3 [8.3%] vs 15 [41.7%], P = 0.01). The rate of 
major or CRNM bleedings was 5.8%/year on apix‑
aban compared with 28.4%/year on other antico‑
agulant regimens (HR, 0.23; 95% CI, 0.05–0.70; 
P = 0.008). There were 2 major bleedings among 
patients treated with apixaban (2.5 mg twice dai‑
ly) and 12 major bleedings in controls (3.9%/year 
and 22.7%/year, respectively; HR, 0.18; 95% CI, 
0.03–0.7; P = 0.009). There was 1 CRNM bleeding 
on apixaban and 3 CRNM bleedings in the control 
group (1.9%/year and 5.7%/year, respectively; HR, 
0.46; 95% CI, 0.02–3.66; P = 0.5). Gastrointesti‑
nal bleedings were less frequent among patients 
switched to apixaban (1 [2.8%] vs 8 [22.3%], 
P = 0.03), and the risk of gastrointestinal bleed‑
ing on apixaban was decreased compared with 
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In conclusion, the current small study shows 
the first Polish experience with the use of apixa‑
ban in patients at high bleeding risk, given the low 
availability of this agent due to no reimburse‑
ment of such therapy for AF and VTE in Poland.
Supplementary material Supplementary materi‑
al is available with the article at www.pamw.pl.
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TABLE 1 Characteristics of study participants
Variable Apixaban‑treated patients
(n = 36)
Controls
(n = 36)
P value
Demographic characteristics
Age, y, median (IQR) 75 (66.8–79.8) 74.5 (65.5–78.8) 0.7
Female sex, n (%) 18 (50) 20 (55.6) 1.0
Body mass index, kg/m2, median (IQR) 26.7 (24.1–28.9) 24.6 (21.9–32.8) 1.0
Indication for anticoagulation, n (%) Venous 
thromboembolism
7 (19.5) 7 (19.5) 0.9
Atrial fibrillation 30 (83.3) 30 (83.3)
Time since diagnosis, y, median (IQR) 6 (2.6–12.8) 8 (5–10.8) 0.3
Time of anticoagulant treatment 
before enrollment, y, median (IQR)
3 (1–6) 3 (1–4) 0.4
Risk of stroke and bleeding in AF patients
CHA2DS2 ‑VASc, median (IQR) 4.5 (4–5) 4.5 (4–5) 1.0
CHA2DS2 ‑VASc ≥2, n (%) 30 (83.3) 30 (83.3) 1.0
HAS ‑BLED, median (IQR) 4 (3–5) 4 (3–4) 1.0
HAS ‑BLED ≥3, n (%) 29 (96.7) 28 (93.3) 1.0
Comorbidities, n (%)
Heart failure 15 (41.7) 10 (13.9) 0.3
Previous ischemic stroke 10 (13.9) 10 (13.9) 1.0
Peptic ulcer disease 10 (27.8) 8 (22.2) 0.8
Abnormal liver function 4 (11.1) 4 (11.1) 1.0
Medications, n (%)
Acetylsalicylic acid 6 (16.7) 7 (19.5) 1.0
Amiodarone 4 (11.1) 2 (5.6) 0.7
Proton pump inhibitors 24 (66.7) 29 (80.6) 0.3
Laboratory investigations
Hemoglobin, g/l, median (IQR) 129 (111–140) 138 (127–147) 0.03
Platelets, × 109/l, mean (SD) 225 (88.9) 192 (48.1) 0.05
eGFR, ml/min/1.73 m2, median (IQR) 77 (44.25–91) 59 (43.50–65) 0.03
eGFR <60 ml/min/1.73 m2, n (%) 16 (44.4) 18 (50) 0.2
Bleeding before enrollment, n (%)
Severe gastrointestinal bleeding 16 (44.4) 16 (44.4) 1.0
Heavy menstrual bleeding 4 (11.1) 4 (11.1) 1.0
Intracranial hemorrhage 3 (8.3) 3 (8.3) 1.0
Hemoptysis 2 (5.6) 2 (5.6) 1.0
Other 7 (19.4) 7 (19.4) 1.0
Abbreviations: eGFR, estimated glomerular filtration rate; IQR, interquartile range; CHA2DS2 ‑VASc and HAS ‑BLED, see the Material and methods section
